Legislation Details

File #: 14489   
Type: Consent Status: Agenda Ready
File created: 6/11/2026 Department: Arrowhead Regional Medical Center
On agenda: 6/23/2026 Final action:
Subject: Agreement with Edwards Lifesciences, LLC for the Purchase of Various Products Used to Treat Severe Aortic Valve Stenosis or Restenosis
Attachments: 1. ADD-COV - ARMC - 6-23-26 - Edwards Lifesciences, 2. ADD-CON - ARMC - 6-23-26 - Edwards Lifesciences (Final)
Date Action ByActionResultAction DetailsAgenda DocumentsVideo
No records to display.

REPORT/RECOMMENDATION TO THE BOARD OF SUPERVISORS

OF SAN BERNARDINO COUNTY

AND RECORD OF ACTION

 

                                          June 23, 2026

 

FROM

ANDREW GOLDFRACH, ARMC Chief Executive Officer, Arrowhead Regional Medical Center 

         

SUBJECT                      

Title                     

Agreement with Edwards Lifesciences, LLC for the Purchase of Various Products Used to Treat Severe Aortic Valve Stenosis or Restenosis

End

 

RECOMMENDATION(S)

Recommendation

Approve Agreement with Edwards Lifesciences, LLC, for the purchase of SAPIEN 3 Ultra RESILIA transcatheter heart valves, Commander Delivery Systems, and related products used to treat severe aortic valve stenosis or restenosis, in the amount of $5,100,000, for a term of June 23, 2026 through June 22, 2031.

(Presenter: Andrew Goldfrach, ARMC Chief Executive Officer, 580-6150)

Body

 

COUNTY AND CHIEF EXECUTIVE OFFICER GOALS & OBJECTIVES

Provide for the Safety, Health and Social Service Needs of County Residents.

 

FINANCIAL IMPACT

Approval of this item will not result in the use of Discretionary General Funding (Net County Cost), as the not-to-exceed cost of $5,100,000 is funded by State Medi-Cal, Federal Medicare, private insurances, and other departmental revenue. Funding sources may change in the future pending any legislative activity related to the repeal and/or replacement of the Affordable Care Act. Adequate appropriation and revenue have been included in the Arrowhead Regional Medical Center (ARMC) 2025-26 budget and will be included in future recommended budgets.

 

BACKGROUND INFORMATION

The Agreement with Edwards Lifesciences, LLC (Edwards) will enable ARMC to purchase SAPIEN 3 Ultra RESILIA transcatheter heart valves, Commander Delivery Systems, and related structural heart products necessary to establish and support ARMC’s planned Transcatheter Aortic Valve Replacement (TAVR) program.

 

TAVR is a minimally invasive heart procedure to treat severe aortic stenosis, a narrowing of the aortic valve, restricting blood flow from the heart to the body. The addition of the procedure will allow ARMC to provide treatment for patients requiring the procedure, instead of them being referred out to an outside hospital. In addition, the procedure further strengthens the Structural Heart Program and enhances ARMC’s ability to provide comprehensive, specialized cardiac care to patients within the community.

 

ARMC recommends approval of the agreement with Edwards to allow ARMC to procure TAVR products to support patient care.

 

PROCUREMENT

Purchasing supports this non-competitive procurement based on functional specifications. Edwards is the only qualified vendor that meets the required functional specifications and provides the necessary products and related support services for ARMC’s TAVR program. The Edwards SAPIEN 3 Ultra RESILIA transcatheter heart valve platform, associated delivery systems, physician training, clinical support, and consignment inventory services are required to support implementation and operation of ARMC's TAVR program.

 

REVIEW BY OTHERS

This item has been reviewed by County Counsel (Daniella Hernandez, Deputy County Counsel, 387-5455) on May 14, 2026; Purchasing (Veronica Pedace, Buyer III, 387-2464) on May 21, 2026; ARMC Finance (Chen Wu, Finance and Budget Officer, 580-3165) on May 29, 2026; and County Finance and Administration (Jenny Yang, Administrative Analyst, 387-4884) on June 6, 2026.